Form 4: Alnylam Pharmaceuticals Director Dennis Ausiello Executes Stock Options and Sells Shares Under 10b5-1 Plan

Director Dennis Ausiello exercised stock options and sold shares of Alnylam Pharmaceuticals under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On August 6, 2024, Dennis Ausiello, a director of Alnylam Pharmaceuticals, exercised stock options to acquire 20,250 shares of common stock.
• These options were exercised at strike prices of $105.26 and $131.21.
• Concurrently, Ausiello sold 19,688 shares of Alnylam common stock at prices ranging from $259.56 to $266.45.
• These transactions were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on May 3, 2024.
• Following these transactions, Ausiello directly owns 4,438 shares and indirectly owns 3,500 shares through a trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the director's outlook on the company.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.

Risks

• While the transactions are under a 10b5-1 plan, large sales by insiders can sometimes be perceived negatively by the market.

Future Outlook

The document does not contain any specific forward-looking statements.

Industry Context

Insider transactions are common in the pharmaceutical industry. Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.

Comparison to Industry Standards

• It's common for executives at publicly traded companies like Alnylam, Regeneron, and Vertex Pharmaceuticals to have stock option plans as part of their compensation.
• The use of 10b5-1 trading plans is a standard practice among corporate insiders to avoid accusations of illegal insider trading.
• The size and frequency of these transactions are typical for directors at similar-sized biotech companies.

Stakeholder Impact

• The transactions could have a minor impact on shareholders due to the increased supply of shares in the market.

Key Dates